



THE FORUM
For Collaborative ResearchSM

Combination Therapy WG

Liver Forum 16 Update

Washington DC

23 March 2024

Michelle T. Long, MD, MSc

Novo Nordisk, DK

on behalf of the combination therapy WG

Berkeley Public
Health

Working group progress:




Co-chairs: **Alina Allen** (Mayo) and **Michelle Long** (Novo Nordisk)

Meetings: Approximately 1x per month

- Alina Allen
- Roberto Calle
- Henry Chang
- Claudia Filozof
- Joanne Imperial
- Madhuri Jerfy
- Sehyr Khan
- Michelle Long
- Libette Luce
- Veronica Miller
- Paul Nitschmann
- Melissa Palmer
- Vlad Ratziu
- Andrea Ribeiro
- Detlef Schuppan
- Abhinav Seth
- Raj Vuppalanchi
- Pam Danagher
- Diogo Ferrinho
- Michael Fuchs
- Azza Karrar
- Sanjay Kumar
- Ruby Mehta
- Mazen Nouredin
- Cathy O'Hare
- Brenda Rodriguez
- Charmaine Stewart
- Pam Young


Combination therapy may most effectively treat MASH



How do we approach combination therapy for patients with MASH?

Trial 1


- Time driven by biopsy/histology
- Non-cirrhotic NASH



OR

Trial 2

- Time driven by biopsy/histology
- Non-cirrhotic NASH



How to minimize monotherapy arms?

- Can we extrapolate from historical studies using same or similar molecules for diseases with overlapping phenotypes?
- Can we extrapolate from phase 2 data?
- Can we consider non-histologic surrogates/NITs for monotherapy arms?

2 Identified Workstreams

- 1: Explore the regulatory landscape for combination therapies in MASH
 - Describe current guidance, highlight challenges, describe consensus suggestions which may mitigate challenges
- 2: Consensus statement on combination therapies
 - Consider different MASLD phenotypes (low, mid, high risk of MALO)
 - Mechanistic rationale for combination therapies
 - Inventory of MoA and build consensus around prioritized combinations

Plan: Consensus recommendations on combination drug development

- Aim: combine clinical, drug development and regulatory considerations in single consensus paper
 - Draft paper under development

Draft: Anticipating the Future of Combination Therapy Trial Designs in MASH Clinical Trials- Considerations

Contents

Introduction.....	2
Section 2 Specific drug considerations.....	3
Section 3.....	6
Pros/cons for investigating different combination approaches.....	6
Section 4.....	7
Regulatory Guidance: Outline FDA and EMA draft guidance documents from a combination therapy perspective.....	7
Major Points of Agreement.....	8
Unique Points.....	9
Noncirrhotic NASH.....	10
Combination Product Development in the setting of MASH.....	13
Pediatric Considerations.....	14
Section 5.....	15
Specific challenges for MASH clinical trial design.....	15
Considerations for Phase 2 Combination Therapy Clinical Trials.....	16
Considerations for Phase 3 Combination Therapy Clinical Trials.....	16
Areas for Innovation in Clinical Trial Design.....	17
Hybrid RWE-RCT Design.....	17
Section 6.....	18
References.....	19

Next steps



- Finalize central figure
- Continue to add details to several paper sections
- Anticipate having draft available for broader comments by end of June 2024, paper submission by Aug 2024.